Vemana Goutham, Kim Eric H, Bhayani Sam B, Vetter Joel M, Strope Seth A
Department of Surgery, Division of Urology, Washington University in St. Louis, School of Medicine, St. Louis, MO.
Department of Surgery, Division of Urology, Washington University in St. Louis, School of Medicine, St. Louis, MO.
Urology. 2016 Sep;95:115-20. doi: 10.1016/j.urology.2016.05.033. Epub 2016 May 24.
To determine survival differences among patients receiving endoscopic vs surgical management for upper tract urothelial carcinoma (UTUC).
Using Surveillance, Epidemiology and End Results-Medicare data, patients diagnosed with nonmuscle-invasive, low-grade UTUC as their first cancer diagnosis between 2004 and 2009 were identified. Receipts of endoscopic and surgical interventions were assessed, and patients were separated into surgical or endoscopic management cohorts. Two-to-one propensity score analysis was performed to control for baseline characteristics between groups.
The endoscopic management (n = 151) and matched surgical management (n = 302) groups demonstrated no significant differences in age, gender, race, marital status, Charlson comorbidity index, or year of diagnosis. Endoscopic management was an independent and significant predictor of all-cause and cancer-specific mortality (hazard ratio 1.6 for overall survival [OS], hazard ratio 2.1 for cancer-specific survival [CSS]). Kaplan-Meier estimated survival was significantly lower for endoscopic management, with both OS and CSS curves diverging at approximately 24-36 months. A subset of patients initially receiving endoscopic management went on to receive surgical intervention (80/151 = 53%) at a median of 8.8 months from diagnosis. For these patients, Kaplan-Meier-estimated CSS was not significantly different from those who continued with only endoscopic management, and remained significantly lower than patients who received upfront surgery.
Although initial survival outcomes (first 24 months) are similar for endoscopic and surgical management of nonmuscle-invasive, low-grade UTUC, both CSS and OS are significantly inferior for the endoscopic management group in the longer term. Furthermore, transition from initial endoscopic management to surgical intervention appears to have limited impact on survival.
确定接受内镜治疗与手术治疗的上尿路尿路上皮癌(UTUC)患者之间的生存差异。
利用监测、流行病学和最终结果-医疗保险数据,确定2004年至2009年间被诊断为非肌层浸润性、低级别UTUC且为首次癌症诊断的患者。评估内镜和手术干预的接受情况,并将患者分为手术治疗或内镜治疗队列。进行二比一倾向评分分析以控制组间的基线特征。
内镜治疗组(n = 151)和匹配的手术治疗组(n = 302)在年龄、性别、种族、婚姻状况、查尔森合并症指数或诊断年份方面无显著差异。内镜治疗是全因死亡率和癌症特异性死亡率的独立且显著预测因素(总生存[OS]的风险比为1.6,癌症特异性生存[CSS]的风险比为2.1)。内镜治疗的Kaplan-Meier估计生存率显著较低,OS和CSS曲线在约24 - 36个月时出现分歧。一部分最初接受内镜治疗的患者在诊断后中位数8.8个月继续接受了手术干预(80/151 = 53%)。对于这些患者,Kaplan-Meier估计的CSS与仅继续接受内镜治疗的患者无显著差异,且仍显著低于接受 upfront手术的患者。
尽管非肌层浸润性、低级别UTUC的内镜治疗和手术治疗的初始生存结果(前24个月)相似,但从长期来看,内镜治疗组的CSS和OS均显著较差。此外,从初始内镜治疗过渡到手术干预对生存的影响似乎有限。